文献速递复苏、休克与脓毒症

肠内氨甲环酸减轻失血性休克中的血管升压药抵抗并改变α1肾上腺素能受体表达

Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock.
PubMed 文献 · J Trauma Acute Care Surg · 2017-01-01
一句话结论大鼠失血性休克模型中,肠内给予氨甲环酸可恢复对去氧肾上腺素的血压反应并恢复α1受体密度,提示肠腔蛋白酶抑制可能改善血流动力学。

该研究在大鼠失血性休克模型(平均动脉压35 mm Hg持续2小时,再灌注2小时)中,于休克诱导后1小时经小肠和盲肠肠内注射蛋白酶抑制剂氨甲环酸(127 mM)。结果显示,休克动物再灌注后对去氧肾上腺素(2 μg/kg)的血压反应(持续时间和幅度)较基线和对照非休克动物显著减弱,肠内氨甲环酸可使其恢复至接近基线;休克动物动脉α1受体密度降低,肠内氨甲环酸治疗后恢复至基线;体外实验中,休克血浆降低平滑肌细胞α1受体密度,肠内氨甲环酸治疗亦可消除这一效应。作者认为,小肠腔内蛋白酶抑制可改善失血性休克血流动力学,可能通过恢复维持全身血压和灌注所需的α1肾上腺素能功能实现。

要点

  • 大鼠失血性休克(平均动脉压35 mm Hg持续2小时,再灌注2小时)后,对去氧肾上腺素(2 μg/kg)的血压反应持续时间和幅度较基线及对照非休克动物显著减弱。
  • 休克诱导后1小时经小肠和盲肠肠内给予氨甲环酸(127 mM),可使再灌注后对去氧肾上腺素的血压反应恢复至接近基线。
  • 休克动物动脉α1受体密度降低,肠内氨甲环酸治疗后恢复至基线;体外休克血浆降低平滑肌细胞α1受体密度,氨甲环酸治疗可消除该效应。
  • 作者认为,小肠腔内蛋白酶抑制可改善失血性休克血流动力学,可能通过恢复α1肾上腺素能功能实现。

适用人群与场景

  • 大鼠实验性失血性休克模型:平均动脉压35 mm Hg持续2小时,随后再灌注2小时。

处置流程与药物剂量

  • 休克诱导后1小时,经小肠和盲肠肠内注射氨甲环酸(127 mM)。
  • 在离散时间点给予去氧肾上腺素(2 μg/kg)以测量血管升压药反应性。

研究设计与关键结果

  • 研究类型:动物实验(大鼠失血性休克模型)加体外实验。
  • 再灌注后对去氧肾上腺素(2 μg/kg)的血压反应(持续时间和幅度)在失血性休克动物中较基线和对照非休克动物显著减弱,肠内氨甲环酸可使其恢复至接近基线。
  • 休克动物动脉α1受体密度降低,肠内氨甲环酸治疗后恢复至基线。
  • 体外实验中,大鼠休克血浆降低平滑肌细胞α1受体密度,肠内氨甲环酸治疗亦可消除该效应。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠)与体外实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,小肠腔内蛋白酶抑制可改善失血性休克血流动力学,可能通过恢复维持全身血压和灌注所需的α1肾上腺素能功能实现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Irreversible hemorrhagic shock is characterized by hyporesponsiveness to vasopressor and fluid therapy. Little is known, however, about the mechanisms that contribute to this phenomenon. Previous studies have shown that decreased intestinal perfusion in hemorrhagic shock leads to proteolytically mediated increases in gut permeability, with subsequent egress of vasoactive substances systemically. Maintenance of blood pressure is achieved in part by α1 receptor modulation, which may be affected by vasoactive factors; we thus hypothesized that decreases in hemodynamic stability and vasopressor response in shock can be prevented by enteral protease inhibition.

METHODS: Rats were exposed to experimental hemorrhagic shock (35 mm Hg mean arterial blood pressure for 2 hours, followed by reperfusion for 2 hours) and challenged with phenylephrine (2 μg/kg) at discrete intervals to measure vasopressor responsiveness. A second group of animals received enteral injections with the protease inhibitor tranexamic acid (TXA) (127 mM) along the small intestine and cecum 1 hour after induction of hemorrhagic shock.

RESULTS: Blood pressure response (duration and amplitude) to phenylephrine after reperfusion was significantly attenuated in animals subjected to hemorrhagic shock compared with baseline and control nonshocked animals and was restored to near baseline by enteral TXA. Arteries from shocked animals also displayed decreased α1 receptor density with restoration to baseline after enteral TXA treatment. In vitro, rat shock plasma decreased α1 receptor density in smooth muscle cells, which was also abrogated by enteral TXA treatment.

CONCLUSION: Results from this study demonstrate that experimental hemorrhagic shock leads to decreased response to the α1-selective agonist phenylephrine and decreased α1 receptor density via circulating shock factors. These changes are mitigated by enteral TXA with correspondingly improved hemodynamics. Proteolytic inhibition in the lumen of the small intestine improves hemodynamics in hemorrhagic shock, possibly by restoring α1 adrenergic functionality necessary to maintain systemic blood pressure and perfusion.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Santamaria MH, Aletti F, Li JB, et al. Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock. J Trauma Acute Care Surg. 2017. PMID: 28422915. doi:10.1097/TA.0000000000001513

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。